The mechanism of action is based on differential methylation profiles between ovarian cancer cell lines at the PARP4 promoter, leading to the conclusion that this MART should be considered a diagnostic marker of great interest (Figure 2) [55]. Here, PARP4 is linked to ovarian carcinoma.